UPSTREAM MG · Frequently asked questions
Questions, answered.
A complete reference of the questions people commonly ask about the UPSTREAM MG study, grouped by topic. If you're ready, you can skip straight to the form.
Study basics
What UPSTREAM MG is and why it's being studied.
What is the UPSTREAM MG study?
The UPSTREAM MG clinical study ( NCT06456580 ) is a global Phase 3 research study evaluating how safe and effective telitacicept may be for adults with generalized myasthenia gravis.
Does registering mean I am in the study?
No. Registering means you are asking to learn more and are willing to be contacted. You would still need to be evaluated for eligibility, complete screening, and sign an informed consent form before you could join the study.
Eligibility
Who the study team is looking for, and how final eligibility is confirmed.
Who may be able to join?
You may be able to join if you are 18 years of age or older, have been diagnosed with generalized myasthenia gravis, and meet the study's medical requirements.1 Final eligibility is determined by the study team during screening.
Can I register if I am not sure this study is right for me?
Yes. Many people register to get more information and talk with the study team before deciding whether to move forward.
Placebo and randomization
How treatment groups are assigned and what a placebo is.
Will everyone receive the study drug?
Yes, but not necessarily at first. During the first treatment period, participants who qualify are randomly assigned to receive either the study drug (telitacicept) or a placebo for 24 weeks. The placebo looks the same but does not contain active ingredients. In the extension period, participants who continue the study receive telitacicept. There is no placebo in the extension phase.1
What is a placebo?
A placebo looks the same as the study drug but does not contain active ingredients. In this study, some participants in the first treatment period receive placebo so researchers can compare results fairly.
Study duration and visits
How long participation may last, and what visits could look like.
How long could participation last?
Participation includes about 4 weeks of screening, a 24-week first treatment period, an extension treatment period of at least 48 weeks, an open-label extension that may continue longer, and an 8-week follow-up. Total time in the study can exceed 84 weeks, depending on how long you continue.1
How often would I have to visit the study site?
The exact visit schedule will be explained by the study team. In general, you can expect regular visits during the screening and treatment periods, with possible home injections between some on-site visits.
Can injections happen at home?
In some cases, yes. Between on-site visits, some injections may be done at home, depending on the protocol and what the study team determines is appropriate. Your study team will explain what applies to you.
Voluntary participation
Your rights as a participant, and how to leave the study at any time.
Is taking part voluntary?
While you can leave the study for any reason or at any time, deciding not to take part will not impact your current or future medical care. Taking part in the UPSTREAM MG study is completely voluntary.
What risks are involved?
All medicines and clinical studies have possible risks, including side effects. The study team will review the known and potential risks and benefits with you before you decide whether to join.
Expenses and support
Reimbursement for reasonable study-related expenses.
Is there help with study-related expenses?
If you qualify and take part, you may receive reimbursement for reasonable study-related expenses, such as travel and parking, as described by the study team.
Caregivers
How a spouse, family member, or friend can help you explore the study.
Can a caregiver register for someone else?
A caregiver, such as a spouse, family member, or close friend, may use the registration form if they are helping an adult with gMG explore this study.
Can a caregiver fill out the form?
Yes. When registering, select the "Someone I care for" option on the form. A member of the study team may then contact the caregiver using the information provided to share more about the study.
After you register
What happens once you submit the form—and what doesn't.
What happens after I register?
A member of the study team may contact you using the information you provide. They can answer questions, explain the study, and discuss possible next steps. Registering means you are asking to learn more and are willing to be contacted—it is not the same as joining the study.
Can I call someone instead of using the form?
Yes. If you'd prefer to speak with someone first, you can call 1-877-513-1460 to learn more about the UPSTREAM MG study.
Locations
Current US study site states and how to check for one near you.
How do I find out if there is a site near me?
You can check the Locations section on the homepage to see the current US cities where study sites are listed. The study team can confirm whether a nearby site is enrolling and whether it may be an option for you.
Get in touch
Ways to reach the study team if you prefer to speak with someone.
Who can I contact with more questions?
You can email study@vorbio.com or call 1-877-513-1460 to speak with a member of the study team.
Reference
Medically reviewed · May 2026
- A study of telitacicept for the treatment of generalized myasthenia gravis (UPSTREAM MG). ClinicalTrials.gov identifier: NCT06456580. Updated May 7, 2026. Accessed May 14, 2026. https://clinicaltrials.gov/study/NCT06456580
Ready when you are
Ready to take the next step?
Registering takes about a minute and is not a commitment to join the study.